- Home
- ASM vs GHRS Comparison
ASM vs GHRS Comparison
Compare ASM & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- GHRS
- Stock Information
- Founded
- ASM 1968
- GHRS 2018
- Country
- ASM Canada
- GHRS Ireland
- Employees
- ASM N/A
- GHRS N/A
- Industry
- ASM Metal Mining
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- ASM Basic Materials
- GHRS Health Care
- Exchange
- ASM Nasdaq
- GHRS Nasdaq
- Market Cap
- ASM 798.8M
- GHRS 892.0M
- IPO Year
- ASM N/A
- GHRS 2021
- Fundamental
- Price
- ASM $5.51
- GHRS $15.17
- Analyst Decision
- ASM Strong Buy
- GHRS Strong Buy
- Analyst Count
- ASM 3
- GHRS 9
- Target Price
- ASM $5.27
- GHRS $30.11
- AVG Volume (30 Days)
- ASM 4.0M
- GHRS 436.7K
- Earning Date
- ASM 11-06-2025
- GHRS 11-06-2025
- Dividend Yield
- ASM N/A
- GHRS N/A
- EPS Growth
- ASM 476.57
- GHRS N/A
- EPS
- ASM 0.14
- GHRS N/A
- Revenue
- ASM $86,065,000.00
- GHRS N/A
- Revenue This Year
- ASM $37.72
- GHRS N/A
- Revenue Next Year
- ASM $26.15
- GHRS N/A
- P/E Ratio
- ASM $37.46
- GHRS N/A
- Revenue Growth
- ASM 58.42
- GHRS N/A
- 52 Week Low
- ASM $0.85
- GHRS $6.72
- 52 Week High
- ASM $6.67
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- ASM 63.80
- GHRS 60.43
- Support Level
- ASM $4.12
- GHRS $13.71
- Resistance Level
- ASM $4.83
- GHRS $15.01
- Average True Range (ATR)
- ASM 0.34
- GHRS 0.94
- MACD
- ASM 0.10
- GHRS 0.11
- Stochastic Oscillator
- ASM 95.61
- GHRS 89.79
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.